THALIX 50 MG

Rather than viewing Thalidomide only as a member of the imid class, its clinical role is better understood through the indications recorded here. Multiple myeloma; selected other hematologic conditions in specific settings is the principal oncology use described in the database. Immunomodulates cytokine signaling, alters cereblon-dependent pathways and has antiangiogenic effects. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. The treatment is classified as Targeted Therapy; Immunomodulatory Agent and is associated with Multiple Myeloma. Regimens listed include Thalidomide + dexamethasone; melphalan/prednisone/thalidomide; myeloma combinations. These examples show where the medicine is incorporated into treatment pathways and, where relevant, which agents accompany it. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Selection should remain anchored to the specific disease context, including any biomarker, receptor, stage, or previous-treatment criterion supplied with the indication. The pharmacologic mechanism provides context but does not by itself establish eligibility. This database entry is intended for clinical reference and not for individualized prescribing, dose selection, or treatment planning. Current product labeling and relevant guideline versions should be used to verify contemporary practice.